Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.68 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.68 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.55 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.55 |
| ▸ | AXL | P30530 | 1/20 | 0.55 |
| ▸ | DHFR | P00374 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 2/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.49 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12129552 | 0.91 | EPHX2 (0.61) | EPHX2PRMT6CYP2A6ALDH1A1CYP3A4 | |
| SCHEMBL21442882 | 0.87 | CYP2A6 (0.58) | EPHX2PRMT6CYP2A6ALDH1A1CYP3A4 | |
| SCHEMBL4468765 | 0.86 | EPHX2 (0.64) | EPHX2PRMT6CYP2A6ALDH1A1CYP3A4 | |
| SCHEMBL16118323 | 0.85 | CYP2A6 (0.56) | EPHX2PRMT6CYP2A6ALDH1A1CYP3A4 | |
| SCHEMBL8241482 | 0.83 | IDO1 (0.51) | EPHX2PRMT6CYP2A6DHFRBACE1 | |
| SCHEMBL29489424 | 0.82 | BCL2 (0.62) | EPHX2PRMT6CYP2A6CYP1A2IDO1 | |
| SCHEMBL5547358 | 0.82 | BCL2 (0.62) | EPHX2PRMT6CYP2A6CYP1A2IDO1 | |
| SCHEMBL2025453 | 0.81 | EPHX2 (0.63) | EPHX2PRMT6CYP2A6ALDH1A1CYP3A4 | |
| SCHEMBL4581739 | 0.81 | MKNK1 (0.68) | EPHX2PRMT6CYP2A6ALDH1A1CYP3A4 | |
| SCHEMBL3780918 | 0.81 | CYP2A6 (0.73) | EPHX2PRMT6CYP2A6ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044778-A2 | NOVEL MODULATORS OF FSHR AND USES THEREOF | CELMATIX INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-11180492-B2 | Anti-parasitic compounds and uses thereof | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| EP-3377060-B1 | PYRAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF | LUNDBECK LA JOLLA RESEARCH CENTER INC (US) | 2020-08-19 | — | — | EP | disclosed |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| WO-2019154366-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏奥赛康药业有限公司 | 2019-08-15 | — | — | WO | disclosed |
| US-20190015411-A9 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20190002463-A1 | ANTI-PARASITIC COMPOUNDS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2019-01-03 | — | — | US | disclosed |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| WO-2018081285-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
| US-20100270915-A1 | Beta-Diketone Ancillary Ligands and Their Metal Complexes Used in Organic Optoelectronic Devices | NATIONAL TSING HUA UNIVERSITY (TW) | 2010-10-28 | — | — | US | disclosed |
| US-7667036-B2 | MAPKAP-K2 (mitogen-activated protein kinase-activated protein kinase 2) inhibitors; inflammatory, autoimmune disease, destructive bone disorder, cancer and/or tumor growth; angiogenesis, diabetes and neurological disorders | TEIJIN PHARMA LIMITED (JP) | 2010-02-23 | — | — | US | disclosed |
| US-20090270381-A1 | Non-steroidal progesterone receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2009-10-29 | — | — | US | disclosed |
| WO-2009077186-A1 | NONSTEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESLLSCHAFT (DE) | 2009-06-25 | — | — | WO | disclosed |
| EP-2070909-A1 | Non-steroidal progesterone receptor modulators | Bayer Schering Pharma AG (DE) | 2009-06-17 | — | — | EP | disclosed |
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| US-7417053-B2 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180492-B2 | Anti-parasitic compounds and uses thereof | MPO, GOT2, GOT1 | EPHX2 1393/4885PRMT6 868/4885CYP2A6 1053/4885 |
| US-20090270381-A1 | Non-steroidal progesterone receptor modulators | PGR, PGRMC1, PGRMC2 | EPHX2 2275/4885PRMT6 2466/4885CYP2A6 134/4885 |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAP4K2, MAPKAPK5 | EPHX2 4017/4885PRMT6 3609/4885CYP2A6 4418/4885 |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | CHUK, BCOR, MYC | EPHX2 4282/4885PRMT6 915/4885CYP2A6 4636/4885 |
| US-20100270915-A1 | Beta-Diketone Ancillary Ligands and Their Metal Complexes Used in Organic Optoelectronic Devices | PBK, DEK, OSTC | EPHX2 3959/4885PRMT6 4198/4885CYP2A6 3797/4885 |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | EPHX2 4282/4885PRMT6 915/4885CYP2A6 4636/4885 |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | EPHX2 3444/4885PRMT6 975/4885CYP2A6 4390/4885 |
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | NR5A1, CYP19A1, GPER1 | EPHX2 2533/4885PRMT6 2405/4885CYP2A6 118/4885 |
| US-20190015411-A9 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | EPHX2 4282/4885PRMT6 915/4885CYP2A6 4636/4885 |
| US-20190002463-A1 | ANTI-PARASITIC COMPOUNDS AND USES THEREOF | MPO, GOT2, GOT1 | EPHX2 1393/4885PRMT6 868/4885CYP2A6 1053/4885 |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | EPHX2 4282/4885PRMT6 915/4885CYP2A6 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.